Benzinga | Jun 11, 2021 07:02AM EDT

Roth Capital Downgrades Ocugen to Neutral, Lowers Price Target to $6

Roth Capital analyst Zegbeh Jallah downgrades Ocugen (NASDAQ:OCGN) from Buy to Neutral and lowers the price target from $10 to $6.